新冠疫苗接种对新冠死亡率及其他原因死亡率的影响,荷兰,2021年1月至2022年1月
研究链接荷兰2021年1月1日至2022年1月31日全国死因、新冠疫苗接种、专科医疗和长期护理报销登记数据,用Cox回归估计疫苗对新冠死亡的有效性及接种后非新冠死亡风险。完成基础免疫2个月后所有年龄组疫苗有效性>90%,随后逐渐下降,首次加强针后回升至>85%;接种后5或8周内非新冠死亡风险较低或相似。结论:人群水平上新冠疫苗接种大幅降低新冠死亡风险,未观察到其他原因死亡风险增加。
要点
- 完成基础免疫2个月后,所有年龄组疫苗对新冠死亡的有效性>90%。
- 基础免疫后7-8个月,多数组有效性降至约80%,高龄长期护理人群和90岁及以上者约60%。
- 首次加强针后所有组疫苗有效性回升至>85%,接种后5或8周内非新冠死亡风险较低或相似。
核心结论
- 人群水平上,新冠疫苗接种大幅降低新冠死亡风险,未观察到其他原因死亡风险增加。
研究设计与样本
- 链接荷兰2021年1月1日至2022年1月31日全国死因、新冠疫苗接种、专科医疗和长期护理报销登记数据,以唯一个人标识符关联。
- 采用Cox回归,以日历时间为基本时间尺度,调整出生年份、性别、医疗风险组和原籍国。
主要发现
- 完成基础免疫2个月后,所有年龄组疫苗对新冠死亡的有效性>90%。
- 基础免疫后7-8个月,多数组疫苗有效性降至约80%,高龄长期护理人群和90岁及以上者约60%。
- 首次加强针后,所有组疫苗有效性回升至>85%。
- 与未接种相比,首次接种后5或8周内非新冠死亡风险较低或相似;与接种一剂相比,第二剂后非新冠死亡风险较低或相似;与接种两剂相比,加强针后非新冠死亡风险较低或相似,适用于所有年龄和长期护理组。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to estimate vaccine effectiveness (VE) against COVID-19 mortality, and to explore whether an increased risk of non-COVID-19 mortality exists in the weeks following a COVID-19 vaccine dose. METHODS: National registries of causes of death, COVID-19 vaccination, specialized health care and long-term care reimbursements were linked by a unique person identifier using data from 1 January 2021 to 31 January 2022. We used Cox regression with calendar time as underlying time scale to, firstly, estimate VE against COVID-19 mortality after primary and first booster vaccination, per month since vaccination and, secondly, estimate risk of non-COVID-19 mortality in the 5 or 8 weeks following a first, second or first booster dose, adjusting for birth year, sex, medical risk group and country of origin. RESULTS: VE against COVID-19 mortality was > 90 % for all age groups two months after completion of the primary series. VE gradually decreased thereafter, to around 80 % at 7-8 months post-primary series for most groups, and around 60 % for elderly receiving a high level of long-term care and for people aged 90+ years. Following a first booster dose, the VE increased to > 85 % in all groups. The risk of non-COVID-19 mortality was lower or similar in the 5 or 8 weeks following a first dose compared to no vaccination, as well as following a second dose compared to one dose and a booster compared to two doses, for all age and long-term care groups. CONCLUSION: At the population level, COVID-19 vaccination greatly reduced the risk of COVID-19 mortality and no increased risk of death from other causes was observed.
引用
- de Gier B, van Asten L, Boere TM, et al. Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021-January 2022. Vaccine. 2023. PMID: 37328352. doi:10.1016/j.vaccine.2023.06.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。